Arizona's 2025 law that would let pharmacies dispense FDA-approved psilocybin the moment the DEA reschedules it out of Schedule I — but changes nothing about legal access today.
Arizona SB 1555 is a conditional-enactment "trigger" law. It says that IF two separate federal actions both happen, Arizona pharmacies may dispense a specific pharmaceutical form of psilocybin as a prescription medication. Until both conditions are met, the law has no practical effect and psilocybin possession remains illegal statewide under Arizona Revised Statutes §13-3401.
The two triggering conditions are: (1) the U.S. Food and Drug Administration approves a crystalline polymorph form of psilocybin as a new prescription drug, and (2) the U.S. Drug Enforcement Administration separately reschedules that approved drug out of Schedule I of the Controlled Substances Act, via an issued federal interim final rule published in the Federal Register. Both conditions must be satisfied by January 1, 2031, or the trigger expires and SB 1555 never activates.
SB 1555 did not start out as a pharmaceutical trigger bill. It was introduced under the reference title "psilocybin services; regulation; licensure" — Arizona legislative shorthand for an Oregon-style regulated psilocybin-services program with licensed service centers and facilitators. That is the same reference title Arizona's 2024 bill, SB 1570, carried the session before.
In March 2025, the House Health and Human Services Committee replaced SB 1555's original service-center text with a strike-everything amendment — a procedural move where a committee deletes a bill's substance and substitutes entirely new text under the same bill number. The replacement text was the much narrower pharmaceutical trigger-law version that ultimately reached the Governor's desk. The regulated-services concept did not survive the amendment.
SB 1555's operative language only permits prescribing "any pharmaceutical composition of crystalline polymorph psilocybin" — a specific, patentable drug formulation, not raw psilocybin mushrooms or a general therapy-access program. That framing matters: it ties Arizona's law to whichever pharmaceutical company eventually wins FDA approval for that exact formulation, rather than creating an open state-licensed market.
Both federal conditions are independent of each other and independent of Arizona. The FDA approval process and the DEA rescheduling process run on separate legal tracks with separate timelines, and neither agency is obligated to act by any particular date. SB 1555 cannot accelerate either federal process — it simply pre-authorizes Arizona pharmacies to dispense the drug the moment both federal boxes are checked, instead of requiring a separate state legislative session to catch up.
The January 1, 2031 deadline is a hard cutoff. If the FDA approval and DEA rescheduling have not both happened by that date, SB 1555's conditional enactment clause lapses and the law does not take effect — Arizona would need new legislation to revisit the question.
SB 1555 establishes the Arizona Psilocybin Advisory Board, housed within the Arizona Department of Health Services (ADHS), with up to 12 members. Members are appointed by the Governor, the Speaker of the House, and the President of the Senate, and serve four-year terms. The statute set a December 31, 2025 deadline for appointments and a March 1, 2026 deadline for the board's first meeting.
The board's role is advisory and preparatory — it studies psilocybin regulation and policy questions so Arizona has a framework ready if the federal trigger fires, but it has no independent authority to grant access, license providers, or change psilocybin's legal status ahead of the FDA/DEA actions. SB 1555 also creates a psilocybin control and regulation fund, financed by future fees and civil penalties, to support the board's and ADHS's work once the program is live.
Arizona lawmakers tried the broader, Oregon-style approach first, and it failed. SB 1570, carrying the identical "psilocybin services; regulation; licensure" reference title, passed both chambers of the Arizona Legislature in 2024 — then Governor Hobbs vetoed it in July 2024. SB 1555 is best understood as the Legislature's second attempt, this time abandoning the licensed-service-center model entirely rather than risk a second veto.
| Feature | SB 1570 (2024) | SB 1555 (2025) |
|---|---|---|
| Model | Oregon-style licensed service centers & facilitators | Pharmaceutical prescription trigger law |
| Substance covered | Psilocybin services generally | Crystalline polymorph psilocybin (specific drug formulation) only |
| Federal dependency | None — would have operated under state law regardless of federal status | Fully contingent on FDA approval + DEA rescheduling by 2031 |
| Outcome | Passed both chambers; vetoed by Gov. Hobbs, July 2024 | Passed both chambers; signed by Gov. Hobbs, June 27, 2025 (Chapter 231) |
| Access created today | Would have created licensed access (moot — vetoed) | None — dormant until federal trigger fires |
The practical lesson is that Arizona's Governor was willing to sign a law about psilocybin only once it stopped creating any actual state-licensed access and instead deferred entirely to federal drug approval. SB 1555 is a much smaller law than SB 1570 would have been — that narrowing is exactly why it survived.
SB 1555 is one of three distinct 2024–2025 Arizona psychedelic measures, and it is easy to confuse them because all three moved through the Legislature within about 18 months of each other:
Arizona also funds a separate ibogaine research program under HB 2871, which is unrelated to psilocybin. Taken together, Arizona has moved more legislation on psychedelics than almost any other state without creating any current public access to any of them — every Arizona measure to date is either research funding, a vetoed access bill, or a dormant federal trigger. For the full state-by-state picture, see the psychedelic legalization tracker.
Arizona SB 1555 creates a conditional trigger law: if the FDA approves a pharmaceutical crystalline polymorph form of psilocybin AND the DEA reschedules it out of Schedule I by January 1, 2031, Arizona pharmacies may dispense it as a prescription medication. Until both federal conditions are met, psilocybin remains fully illegal in Arizona. The law also creates a 12-member Psilocybin Advisory Board and a psilocybin control and regulation fund.
No. SB 1555 changes nothing about psilocybin's legal status today. Psilocybin remains a Schedule I controlled substance under Arizona Revised Statutes §13-3401. SB 1555 only activates prescription access if and when the FDA approves crystalline polymorph psilocybin and the DEA separately reschedules it — neither has happened.
SB 1555 was introduced under the reference title "psilocybin services; regulation; licensure" — an Oregon-style regulated psilocybin-services program, essentially reviving 2024's vetoed SB 1570. The House Health and Human Services Committee replaced that text in March 2025 with a strike-everything amendment, narrowing the bill to the much smaller pharmaceutical trigger-law version that ultimately passed.
Arizona SB 1555 was sponsored by state Senator T.J. Shope (R-Legislative District 16). It passed the Senate and, after the House committee's strike-everything amendment, passed the House 40-19 on June 18, 2025, and was signed by Governor Katie Hobbs, becoming Chapter 231 of the 2025 session laws.
SB 1570 (2024) would have built a full Oregon-style regulated psilocybin-services program with licensed service centers — Governor Hobbs vetoed it in July 2024. SB 1555 (2025) started as the same kind of bill but was gutted by amendment into a narrow pharmaceutical trigger law with no service centers, no licensed facilitators, and no access unless the FDA and DEA both act. It is a much smaller measure that actually became law.
SB 1555 creates a Psilocybin Advisory Board of up to 12 members within the Arizona Department of Health Services, appointed by the Governor, the Speaker of the House, and the President of the Senate. The statute set a December 31, 2025 appointment deadline and a March 1, 2026 first-meeting deadline. The board studies psilocybin policy and regulation ahead of any federal trigger firing — it has no authority to grant access on its own.
SB 1555 only activates if the FDA and DEA both act by 2031. Our legalization tracker follows every state trigger law and the federal actions that could flip them on.
Get Arizona SB 1555 — Psilocybin Prescription Trigger Law updates
New votes, rules, court rulings, and access changes for Arizona SB 1555 — Psilocybin Prescription Trigger Law — delivered when they happen.
← Back to all psychedelic laws
Suggest a tool, topic, or improvement that would make this site more useful.